LONDON, Oct 21 (Reuters) - The University of Oxford's
Brazilian trial of its vaccine candidate will continue after the
death of a volunteer, the university said on Wednesday, adding
an independent review had revealed no safety concerns.
"Following careful assessment of this case in Brazil, there
have been no concerns about safety of the clinical trial and the
independent review in addition to the Brazilian regulator have
recommended that the trial should continue," a spokesman for the
university said in a statement.
The vaccine has been licenced to AstraZeneca.
(Reporting by Alistair Smout
Editing by Chris Reese)
Astrazeneca (AZN)
